- Home
- KOPN vs IMAB Comparison
KOPN vs IMAB Comparison
Compare KOPN & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOPN
- IMAB
- Stock Information
- Founded
- KOPN 1984
- IMAB 2014
- Country
- KOPN United States
- IMAB United States
- Employees
- KOPN N/A
- IMAB N/A
- Industry
- KOPN Semiconductors
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- KOPN Technology
- IMAB Health Care
- Exchange
- KOPN Nasdaq
- IMAB Nasdaq
- Market Cap
- KOPN 277.5M
- IMAB 87.2M
- IPO Year
- KOPN 1992
- IMAB 2020
- Fundamental
- Price
- KOPN $1.82
- IMAB $0.99
- Analyst Decision
- KOPN Strong Buy
- IMAB Strong Buy
- Analyst Count
- KOPN 4
- IMAB 3
- Target Price
- KOPN $2.63
- IMAB $8.00
- AVG Volume (30 Days)
- KOPN 10.3M
- IMAB 274.1K
- Earning Date
- KOPN 03-13-2025
- IMAB 03-13-2025
- Dividend Yield
- KOPN N/A
- IMAB N/A
- EPS Growth
- KOPN N/A
- IMAB N/A
- EPS
- KOPN N/A
- IMAB N/A
- Revenue
- KOPN $44,266,305.00
- IMAB $3,313,984.00
- Revenue This Year
- KOPN $21.18
- IMAB N/A
- Revenue Next Year
- KOPN $13.57
- IMAB N/A
- P/E Ratio
- KOPN N/A
- IMAB N/A
- Revenue Growth
- KOPN 0.60
- IMAB N/A
- 52 Week Low
- KOPN $0.56
- IMAB $0.84
- 52 Week High
- KOPN $2.82
- IMAB $2.08
- Technical
- Relative Strength Index (RSI)
- KOPN 61.10
- IMAB 43.19
- Support Level
- KOPN $1.57
- IMAB $1.03
- Resistance Level
- KOPN $1.99
- IMAB $1.10
- Average True Range (ATR)
- KOPN 0.21
- IMAB 0.06
- MACD
- KOPN 0.02
- IMAB -0.01
- Stochastic Oscillator
- KOPN 69.23
- IMAB 7.58
About KOPN Kopin Corporation
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).